Jošt Vrabič Koren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jošt Vrabič Koren has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Charles Y. Lin
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
13 shared publications - Guillaume Kugener
Broad Institute of MIT and Harvard, Cambridge, MA
13 shared publications - Jazmin Ewers
Harvard Medical School, Boston, MA
13 shared publications - Joshua M. Dempster
Broad Institute of MIT and Harvard, Cambridge, USA
13 shared publications - Jérémie Kalfon
Institut Pasteur, Université Paris Cité
13 shared publications - Kenneth Eagle
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. 3
13 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Transcriptional Plasticity Drives Leukemia Immune Escape
Relapse of acute myeloid leukemia (AML) after allogeneic bone marrow transplantation has been linked to immune evasion due to reduced expression of major histocompatibility complex class II (MHCII) genes through unknown mechanisms. In this work, we developed CORENODE, a computational algorithm for genome-wide transcription network decomposition that identified a transcription factor (TF) tetrad consisting of IRF8, MYB, MEF2C, and MEIS1, regulating MHCII expression in AML cells. We show that reduced MHCII expression at relapse is transcriptionally driven by combinatorial changes in the expression of these TFs, where MYB and IRF8 play major opposing roles, acting independently of the IFNγ/CIITA pathway. Beyond the MHCII genes, MYB and IRF8 antagonistically regulate a broad genetic program responsible for cytokine signaling and T-cell stimulation that displays reduced expression at relapse. A small number of cells with altered TF abundance and silenced MHCII expression are present at the time of initial leukemia diagnosis, likely contributing to eventual relapse.Significance:Our findings point to an adaptive transcriptional mechanism of AML evolution after allogeneic transplantation whereby combinatorial fluctuations of TF expression under immune pressure result in the selection of cells with a silenced T-cell stimulation program.This article is highlighted in the In This Issue feature, p. 369
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Transcriptional Plasticity Drives Leukemia Immune Escape
Relapse of acute myeloid leukemia (AML) after allogeneic bone marrow transplantation has been linked to immune evasion due to reduced expression of major histocompatibility complex class II (MHCII) genes through unknown mechanisms. In this work, we developed CORENODE, a computational algorithm for genome-wide transcription network decomposition that identified a transcription factor (TF) tetrad consisting of IRF8, MYB, MEF2C, and MEIS1, regulating MHCII expression in AML cells. We show that reduced MHCII expression at relapse is transcriptionally driven by combinatorial changes in the expression of these TFs, where MYB and IRF8 play major opposing roles, acting independently of the IFNγ/CIITA pathway. Beyond the MHCII genes, MYB and IRF8 antagonistically regulate a broad genetic program responsible for cytokine signaling and T-cell stimulation that displays reduced expression at relapse. A small number of cells with altered TF abundance and silenced MHCII expression are present at the time of initial leukemia diagnosis, likely contributing to eventual relapse.Significance:Our findings point to an adaptive transcriptional mechanism of AML evolution after allogeneic transplantation whereby combinatorial fluctuations of TF expression under immune pressure result in the selection of cells with a silenced T-cell stimulation program.This article is highlighted in the In This Issue feature, p. 369
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Table from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Table from Transcriptional Plasticity Drives Leukemia Immune Escape
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape